Method for Correcting a Lipid Imbalance in a Subject
AssigneeThe Royal Institution for the Advancement of Learning/Mcgill University
InventorsDanuta Radzioch, Claudine Guilbault, Juan Bautista De Sanctis
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the treatment of a disease or condition associated with lipid imbalance, comprising (a) decreasing arachidonic acid (AA) levels, (b) increasing docosahexaenoic acid (DHA) levels, (c) increasing DHA/AA ratio or (d) any combination of (a)-(c) in a subject using fenretinide. The invention also relates to diagnostic and screening methods based on the determination of lipid levels.
Claims33
A method of (a) decreasing arachidonic acid (AA) levels, (b) increasing docosahexaenoic acid (DHA) levels, c) increasing the DHA/AA ratio, or (d) any combination of (a)-(c) in a subject, said method comprising administering to said subject fenretinide, an analog thereof or a pharmaceutically-acceptable salt thereof.
A method for assessing bone disease in a subject, said method comprising determining whether (a) DHA level is decreased, (b) AA level is increased, (c) DHA/AA ratio is decreased, or (d) any combination of (a) to (c), in a biological sample of said subject;
- relative to a corresponding control level or ratio,
- wherein said increase or decrease is indicative that said subject suffers from bone disease.
A method for determining whether a subject has an increased risk of developing bone disease, said method comprising determining whether (a) DHA level is decreased, (b) AA level is increased, (c) DHA/AA ratio is decreased, or (d) any combination of (a) to (c), in a biological sample of said subject;
- relative to a corresponding control level or ratio,
- wherein said increase or decrease is indicative that said subject has an increased risk of developing bone disease.
A method for identifying a compound for treating or preventing bone disease, comprising determining whether (a) DHA level is decreased, (b) AA level is increased, (c) DHA/AA ratio is decreased, or (d) any combination of (a) to (c), in the presence versus the absence of a test compound,
- wherein said increase or decrease is indicative that said test compound can be used for treating or preventing bone disease.
A method of treating a disease or condition associated with a lipid imbalance in a subject, said method comprising:
- (i) assessing (a) DHA level, (b) AA level, (c) DHA/AA ratio, or (d) any combination of (a) to (c), in a biological sample obtained from said subject;
- and
- (ii) administering fenretinide, an analog thereof or a pharmaceutically-acceptable salt thereof to said subject if said (a) DHA level is decreased, (b) AA level is increased, (c) DHA/AA ratio is decreased, or (d) any combination of (a) to (c), relative to a corresponding control level or ratio.
The method of claim 44, wherein said infectious disease is an opportunistic infection.
The method of claim 45, wherein said bone disease is osteopenia or osteoporosis.
26-39. (canceled)
Dependencies are inferred from the claim text.